


BC Platforms to enable longitudinal RWD and Genomics access for drug development in Africa

13 September 2021 | News

Real-world data (RWD) from the new African Institute of Everyone Genome (AiEG) biobank, aiming to collect 10M+ consenting patients' data



BC Platforms (BCP), a global leader in genomics research, analytics and global data access, announced a new collaboration with the African Institute of Everyone Genome (AiEG), a South African genomic company focusing on building the largest integrated clinical and genomics data biobank in the African continent.

As part of the collaboration, BCP's platform will enable RWD research involving 10M+ consenting patient genomes from all 54 African countries, to be collected by AiEG over a period of 10-15 years. The main goal of the research will be to enable drug development and clinical research for patients in sub-Saharan Africa.

As part of the Strategic Data Partnership with AiEG, BC Platforms is providing a cloud-based, scalable Discovery and Research Platform, made available to AiEG and commercial researchers via Microsoft Azure.

AiEG has built a large footprint of public and private healthcare entities and experienced research clinicians who consent patients for sharing clinical and genomic data for research. The first pilot cohort of patients is anticipated to be engaged in October 2021. BCP's role will enable research collaborations with drug developers, data management and preparation of analysis-ready datasets and leading with global best practices in patient data privacy and security.

Tero Silvola, CEO, BCP, said: "Supporting regional genomics initiatives and RWE research is an important part of our vision to build the world's leading analytics platform enabling rapid drug development. As BCP's technology and approach are focused on best-in-practice governance with respect to biological samples and longitudinal medical record data, we can help ensure the highest quality standards to support research that will have significant positive impact on the African population."

Joe Mojapelo, CEO, AiEG, said: “Our goal is for African DNA to be studied on its own and be part of clinical trials for new and novel therapies treating a truly global population. Through the RWE that will be produced by future studies in collaboration with BCP, leveraging their integrated cloud-based platform alongside our region-leading database.”